BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Ophthalmology

AAV2-Mediated Subretinal Gene Transfer of hIFN-a Attenuates Experimental Autoimmune Uveoretinitis in Mice
Published: Tuesday, May 17, 2011
Author: Lichun Tian et al.

by Lichun Tian, Peizeng Yang, Bo Lei, Ju Shao, Chaokui Wang, Qin Xiang, Lin Wei, Zhougui Peng, Aize Kijlstra

Background

Recent reports show that gene therapy may provide a long-term, safe and effective intervention for human diseases. In this study, we investigated the effectiveness of adeno-associated virus 2 (AAV2) based human interferon-alpha (hIFN-a) gene therapy in experimental autoimmune uveoretinitis (EAU), a classic model for human uveitis.

Methodology/Principal Findings

An AAV2 vector harboring the hIFN-a gene (AAV2.hIFN-a) was subretinally injected into B10RIII mice at two doses (1.5×106 vg, 1.5×108 vg). AAV2 vector encoding green fluorescent protein (AAV2.GFP) was used as a control (5×108 vg). The expression of hIFN-a in homogenized eyes and serum was detected by ELISA three weeks after injection. The biodistribution of vector DNA in the injected eyes, contralateral eyes and distant organs was determined by PCR. EAU was induced by immunization with IRBP161–180 three weeks following vector injections, and evaluated clinically and pathologically. IRBP-specific proliferation and IL-17 expression of lymphocytes from the spleen and lymph nodes were assayed to test the influence of the subretinal delivery of AAV2.hIFN-a on the systemic immune response. hIFN-a was effectively expressed in the eyes from three weeks to three months following subretinal injection of AAV2.hIFN-a vector. DNA of AAV2.GFP was observed only in the injected eyes, but not in the distant organs or contralateral eyes. Subretinal injection of both doses significantly attenuated EAU activity clinically and histologically. For the lower dose, there was no difference concerning lymphocyte proliferation and IL-17 production among the AAV2.hIFN-a, AAV2.GFP and PBS injected mice. However, the higher dose of AAV2.hIFN-a significantly suppressed lymphocyte proliferation and IL-17 production.

Conclusions/Significance

Subretinal delivery of AAV2.hIFN-a lead to an effective expression within the eye for at least three months and significantly attenuated EAU activity. AAV2.hIFN-a was shown to inhibit the systemic IRBP-specific immune response.

  More...

 

//-->